Alumis Inc.
ALMS
Clasificación en acciones
#10082
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Precio por acción
$6.59
Capitalización bursátil
$852.98M
Cambio (1 día)
3.94%
Cambio (1 año)
190.31%
País
US
Comercio Alumis Inc. (ALMS)
Categoría
Healthcare
Ganancias de Alumis Inc. (ALMS)
Ganancias en Mar 2025 TTM: $-268.52M
Secondo gli ultimi rapporti finanziari di Alumis Inc., gli utili attuali della società sono $-268.52M. Nel 2023, la società ha registrato un utile di $-381.64M, una disminución en comparación con agli utili del 2022, che erano di $-64.77M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Alumis Inc. desde 2021 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-268.52M | 8.17% |
| 2024 | $-248.23M | -34.96% |
| 2023 | $-381.64M | 489.21% |
| 2022 | $-64.77M | 54.81% |
| 2021 | $-41.84M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -2,064.46% |
US
|
|
| $-3.09B | 1,049.65% |
US
|
|
| $-4.02B | 1,395.70% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -826.45% |
NL
|
